Classification explainer

Retatrutide legal status: research chemical is not a legal class

By the Decadewise team Education only Last updated 9 August 2026 Regulator documents, not a protocol

Short answer

What it is: retatrutide, development code LY3437943, is an investigational agonist at the GLP-1, GIP and glucagon receptors. No approved application for it exists in the United States, which is the jurisdiction every source on this page speaks to.

What that makes it: a new drug under section 201(p) of the Federal Food, Drug, and Cosmetic Act, and an unapproved one. That is the phrase FDA uses in its own letters to firms selling it.

Why it is not a prescription drug: section 505(a) keeps an unapproved new drug off the market entirely. No approved retatrutide application exists, so no lawfully marketed product exists for a prescription to reach.

Research chemical is not a legal class: FDA has written that a Research Use Only label does not decide the question. Intended use decides it, and a seller's own marketing supplies the evidence.

Not a controlled substance: retatrutide appears in none of the five schedules at 21 CFR 1308.11 to 1308.15.

On this page

Short answer What the records say Is research chemical a legal class? Is it a prescription drug? Can a pharmacy compound it? Export only, in the FDA database What is lawful before approval? Is it banned in sport? What this page cannot settle The safety picture How this is sourced Related pages The disclaimer

What do the agency records actually say?

How to read this: every row is a database or document we queried directly on 9 August 2026, not a summary of one. The retrieval status for each is printed in the source list.

Five records, read at source

Record	What it holds for retatrutide
Drugs@FDA, the approvals database	no matching record; the same query shape returns approved applications for tirzepatide, so the query works and the answer is a real absence
FDA warning letters	three letters between December 2024 and March 2026 name retatrutide products as unapproved new drugs under section 505(a)
Controlled substance schedules, 21 CFR 1308.11 to 1308.15	absent from all five; nandrolone, oxandrolone and boldenone are present in the same files, so the search reaches what it should
FDA drug listing, finished products	ten labeling records filed on one day in November 2025 by one cross-border e-commerce firm, every one under the marketing category Export only
WADA 2026 Prohibited List	not named anywhere in the text; class S0 reaches it by description rather than by name

A listing record is a filing made by a company. It is not a finding by FDA, and it is not an approval.

The pattern across all five: retatrutide is present in the systems that record what exists, and absent from the one system that records what is approved. Nothing in that pattern is ambiguous, and none of it depends on reading an agency's silence.

Is research chemical a legal category?

No. It is a sales label, and FDA has said so in writing to firms that used exactly that wording. Writing to Swisschems on 10 December 2024, the agency put it this way: "Despite statements on your product labeling marketing your products as 'research chemicals only,' evidence obtained from your website establishes that your products are intended to be drugs for human use."

The same answer, a second time: the letter to Gram Peptides of 31 March 2026 replaces one disclaimer with two and reaches the identical conclusion, that despite labeling for "Research Use Only" and "not intended for human consumption, medical use, or veterinary use," the evidence establishes the products are intended to be drugs for human use.

Why the label carries no weight: section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act defines a drug by what an article is intended for, not by what its packaging disclaims. A seller who explains that a compound reduces appetite has supplied the intended use themselves, and in both letters the agency quoted the seller's own product page back at them.

The classification that follows: not generally recognized as safe and effective for those uses, therefore a new drug under section 201(p), therefore barred from interstate commerce without an approved application by sections 301(d) and 505(a). Ostarine reached the same destination by a different route.

Is retatrutide a prescription drug?

No, and the reason matters more than the answer. Section 503(b)(1) of the Act, 21 U.S.C. 353(b)(1), describes which drugs may be dispensed only on a prescription. It does not authorize the sale of a drug that section 505(a) keeps off the market in the first place.

The order of operations: approval comes first, and the prescription category attaches afterward to a product that has one. With no approved application there is no approved labeling, no Rx legend, and nothing for a prescription to be written against. A prescription cannot create a lawfully marketed product that does not exist.

What that separates it from: tirzepatide and semaglutide are prescription drugs because approved applications and approved labels exist for them, which is why their labels can be compared at all. Retatrutide has neither, so there is no label to read and no approved strength to check a vial against.

Can a pharmacy compound it?

No, and FDA has published the reasoning rather than left it to be inferred. The letter to GLP-1 Solution of 9 September 2025 closes both compounding routes in two sentences, each carrying its own list of reasons.

Section 503A, the pharmacy route

The agency's words: drug products compounded using retatrutide are not eligible for the exemptions provided by section 503A, because retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list.

Section 503B, the outsourcing facility route

The agency's words: drug products compounded using retatrutide are not eligible for the exemptions provided by section 503B, because retatrutide does not appear on the 503B bulks list, and is not used to compound a drug that appears on the drug shortage list.

Five qualifications, none of them held: read together, the two sentences check a monograph, membership of an approved product, the 503A list, the 503B list and the shortage list. Any one of them would have opened a route. The agency looked at all five and recorded a miss on every one.

What the same letter adds: because the conditions for treating obesity are not amenable to self-diagnosis and treatment by a layman, "adequate directions for use cannot be written so that a layman can use these products safely for their intended use." That makes the products misbranded under section 502(f)(1) on top of being unapproved.

What does an export-only listing say in law?

The category is defined, not descriptive: a structured product label carries a marketing category from a controlled vocabulary, and on every retatrutide finished-product filing in DailyMed it reads Export only. Nobody typed that phrase as a summary. It is a claim to a specific statutory exemption.

Which exemption: section 801(e)(1) of the Act, 21 U.S.C. 381(e)(1), says a drug intended for export is not deemed adulterated or misbranded if it meets four conditions. It has to accord to the foreign purchaser's specifications, not conflict with the destination country's laws, and say on the outside of the shipping package that it is intended for export.

The fourth condition is the one worth reading: the article "is not sold or offered for sale in domestic commerce." So the filing is the filer's own written statement that this product is not for this market. Read as permission to sell here, it says the reverse of what it says.

What the paperwork still cannot tell you: a filing is a company's assertion, not an analysis anyone performed. It fixes no specification, and it establishes nothing about identity, strength or purity in a given vial, which is a question that a certificate of analysis only partly answers.

The rule the developer lives under

If it cannot be sold, how does anyone get it?

Not through commerce, which is the whole design: 21 CFR 312.7 bars a sponsor from representing an investigational drug as safe or effective for the use under study, and subsection (b) bars commercially distributing or test marketing it outright.

The regulation says why in its own text: the intent is to restrict promotional claims for a use under investigation and to "preclude commercialization of the drug before it is approved for commercial distribution." An unapproved drug is not a product with paperwork missing. It is a thing the law is holding out of the market on purpose, until evidence closes the question.

What that leaves: access happens under the investigational application rather than by sale, through a trial or through pre-approval expanded access, each requiring a physician and a written justification. The routes and their eligibility conditions are documented on the approval status page.

What none of it includes: a checkout page. All three firms named below were selling outside both routes, which is why each letter addresses the act of selling rather than the substance itself.

Is retatrutide banned in sport?

Not by name. We read the 2026 Prohibited List in full and searched it for retatrutide, tirzepatide, semaglutide and incretin. None of the four appears. BPC-157 does appear, which is how we know the search was reaching the text rather than failing quietly.

Why that settles less than it looks: class S0 is written to catch substances by description instead of by name. It covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use," and its first worked example is drugs under pre-clinical or clinical development.

What the clause turns on: approval status, tested against every governmental health authority rather than one. We can state the United States half of that input, which is that no approved application exists. Applying the rest of it to a named athlete is work for their own anti-doping organization, and S0 substances are prohibited at all times, in and out of competition.

The same clause, the opposite result: bremelanotide is not caught by S0, because an approval exists for it. One sentence of the anti-doping code separates the two compounds, and it turns on approval status rather than on chemistry or on effect.

What this page cannot settle

Four limits, stated rather than implied:

Jurisdiction. Every source above is United States federal law or an international sporting standard. State law, and the law of every other country, are separate questions this page does not answer.
What is in a vial. No approved specification exists, so nothing establishes identity, strength or purity for material sold under this name. A certificate supplied by a seller is not that, and neither is a purity number on its own.
Enforcement reach. A warning letter is addressed to one firm. It records the agency's position on the compound, and it is not a finding about every other seller.
The moving part. Approval status is what changes, and the classification on this page changes with it. Everything here describes the position on 9 August 2026.

The safety picture, from the agency record

What the letters state: FDA describes these products as especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. It records that the products are not generally recognized as safe and effective for the uses their sellers describe, and that adequate directions for use cannot be written so that a layman can use them safely. None of that is a finding about a specific batch, and that is the point: with no approved application there is no specification, no release testing anyone is answerable for, and no label. What a given vial contains is unestablished, which is a different and worse problem than a known risk. Anyone weighing this belongs in a conversation with a clinician who can see their history and their labs.

How this page is sourced

Regulators first, and read at source: every quoted sentence was read in the agency document or the statute itself, and every count was produced by querying the named database on 9 August 2026 rather than by reading a search result line about it.

Twelve sources: three agency warning letters, four sections of the United States Code, two sections of the Code of Federal Regulations, one drug listing record, one agency database query, and one international standard read for a negative.

The standard: how we verify a citation, and who reads a page before it ships, is set out in full on our methodology page.

Last reviewed: 9 August 2026.

1
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Warning letter to Gram Peptides, MARCS-CMS 721806, 31 March 2026. Read for the unapproved new drug determination under section 505(a) and for the Research Use Only labeling passage quoted above. Retrieved 9 August 2026, HTTP 200. fda.gov warning letter 721806.
2
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Warning letter to Swisschems, MARCS-CMS 695663, 10 December 2024. Read for the research chemicals only passage quoted above and for the section 201(p) new drug determination. Retrieved 9 August 2026, HTTP 200. fda.gov warning letter 695663.
3
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Warning letter to GLP-1 Solution, MARCS-CMS 715883, 9 September 2025. Read for the section 503A and 503B eligibility findings and the section 502(f)(1) misbranding finding, both quoted above. Retrieved 9 August 2026, HTTP 200. fda.gov warning letter 715883.
4
United States Code, title 21, section 321, Definitions, 2024 edition, subsections (g)(1) and (p), read for the definition of a drug by intended use and the definition of a new drug. Retrieved 9 August 2026, HTTP 200. govinfo.gov, 21 U.S.C. 321.
5
United States Code, title 21, section 355, New drugs, 2024 edition, subsection (a), read for the rule that no person shall introduce or deliver for introduction into interstate commerce any new drug without an effective approval. Retrieved 9 August 2026, HTTP 200. govinfo.gov, 21 U.S.C. 355.
6
United States Code, title 21, section 353, Exemptions and consideration for certain drugs, 2024 edition, subsection (b)(1), read for which drugs are dispensed only on a prescription and on what basis. Retrieved 9 August 2026, HTTP 200. govinfo.gov, 21 U.S.C. 353.
7
United States Code, title 21, section 381, Imports and exports, 2024 edition, subsection (e)(1), read for the four conditions of the export exemption including clause (D), that the article is not sold or offered for sale in domestic commerce. Retrieved 9 August 2026, HTTP 200. govinfo.gov, 21 U.S.C. 381.
8
Code of Federal Regulations, title 21, sections 1308.11 to 1308.15, the five controlled substance schedules, current edition. All five retrieved and searched on 9 August 2026, HTTP 200 each: retatrutide returns zero matches, while nandrolone, oxandrolone and boldenone are present in the same text, which is what establishes that the search reached the schedules rather than failing silently. ecfr.gov, 21 CFR part 1308.
9
Code of Federal Regulations, title 21, section 312.7, Promotion of investigational drugs, subsections (a) and (b), read for the bar on promoting an investigational new drug and on commercially distributing or test marketing it. Retrieved 9 August 2026, HTTP 200. ecfr.gov, 21 CFR 312.7.
10
DailyMed structured product label, SALKALLI (retatrutide pen), labeler Guangzhou Yixin Cross-border E-commerce Co., Ltd., set id 42d6e93c-7d91-e8ec-e063-6294a90a567f, label effective 5 November 2025, published 17 November 2025. The label XML carries marketing category code C73590, Export only. Nine further retatrutide set ids from the same labeler were returned by the same query. Retrieved 9 August 2026, HTTP 200. DailyMed, set id 42d6e93c-7d91-e8ec-e063-6294a90a567f.
11
openFDA, the Drugs@FDA approvals endpoint, queried 9 August 2026. Filtered to generic name retatrutide it returned HTTP 404 carrying the body code NOT_FOUND with the message no matches found. The identical query for tirzepatide returned HTTP 200 with approved applications, which is the control that turns the first result into evidence of absence rather than evidence of a broken query. api.fda.gov, Drugs@FDA query.
12
World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026, in force 1 January 2026, class S0 read in full and the whole document searched for retatrutide, tirzepatide, semaglutide and incretin with no match, and for BPC-157, which is named in S0 and confirms the search reached the text. Automated requests to the agency's own site returned HTTP 202 with an empty body on 9 August 2026, a bot challenge rather than a missing document, so the text was read in two independent published copies of the same standard, both HTTP 200 and identical in S0: the annex to Austrian Federal Law Gazette BGBl. III Nr. 219/2025 of 30 December 2025, and a national federation copy of the English standard. wada-ama.org, the Prohibited List.

Around this page: five neighboring pages on classification, on approval, and on what a vial can be shown to hold.

Retatrutide approval status: the trials, the agency timeline, and the access route this page only points at.
PT-141 and the Vyleesi approval: the same anti-doping clause, landing the other way, because an approval exists.
Is MK-677 a SARM: another compound with no approval anywhere, and the classification it keeps being given.
Tirzepatide vs semaglutide: what two approved incretin labels specify, side by side.
What HPLC purity does not tell you: why one number on a certificate is not an identity check.

One document a week: the regulatory record, pulled apart and posted to The Decadewise briefing.

The disclaimer

Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice. It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.